FINANCIAL STATEMENTS Notes to the Consolidated Financial Statements Continued 38.
Related parties 2014 grants 2013 grants 2012 grants Transactions between the Company and its subsidiaries have been eliminated on consolidation and are not disclosed in this note.
11-Jun 17 May 18 May Total Transactions between the Group and its associates and other related parties are disclosed below.
Year 2014 Number Number Number Number Outstanding at 1 January 243,534 370,468 614,002 Trading transactions: Granted during the year 225,904 225,904 During the year, Group companies entered into the following transactions with related parties: Exercised during the year 5,722 348,506 354,228 Darhold Limited: is a related party of the Group because it is considered one of the major shareholders of Hikma Pharmaceuticals PLC Expired during the year 6,608 8,731 21,962 37,301 with an ownership percentage of 29.06% at end of 2015 2014: 28.8%.
Further details on the relationship between Mr Said Darwazah, Outstanding at 31 December 219,296 229,081 448,377 Mr Mazen Darwazah and Mr Ali Al-Husry, and Darhold Limited are given in the Directors Report.
The cost of the MIP of $6 million 2014: $3 million has been recorded in the consolidated income statement as part of general and Other than dividends as paid to all shareholders, there were no transactions between the Group and Darhold Limited during the year.
Capital Bank - Jordan: is a related party of the Group because two Hikma Pharmaceuticals PLC board members are also board members Executive incentive plan of Capital Bank Jordan.
Additionally a senior member of Hikma management team is a board member of one company owned by Capital The 2014 Executive Incentive Plan EIP was approved by shareholders at the 2014 Annual General Meeting.
The EIP is a combined cash Bank - Jordan.
Total cash balance at Capital Bank Jordan as of 31 December 2015 was $9.4 million 31 December 2014: $5.7 million.
bonus element A, deferred shares element B and restricted share element C scheme.
Under the EIP, the Company makes grants of Utilisation of facilities granted by Capital Bank Jordan to the Group amounted to $nil 31 December 2014: $nil.
Interest expense income conditional awards and $nil cost options under elements B and C to the executive directors and senior executives of the Group.
Awards is within market rate.
under all elements are dependent on the achievement of individual and Group KPIs over one year prior to grant.
The shares awarded under Jordan International Insurance Company: is a related party of the Group because one board member of the Company is also a board element B are not released for a period of two years during which they are subject to a forfeiture condition.
The shares awarded under member of Hikma Pharmaceuticals PLC.
The Group's insurance expense for Jordan International Insurance Company contracts during the element C are not released for a period of three years, but are not subject to a forfeiture condition.
Members of the Executives committee period was $0.5 million 2014: $0.2 million.
The amounts due to Jordan International Insurance Company were $0.4 million 2014: $nil.
must retain 50% of the shares received from elements B and C for a period of five years from the date of grant.
Labatec Pharma: is a related party of the Group because it is owned by the Darwazah family.
During 2015, the Group total sales to Labatec 2015 grants 2015 grants 15-May 10-Apr Total Pharma amounted to $0.9 million 2014: $0.5 million.
At 31 December 2015, the amount owed from Labatec Pharma to the Group was Year 2015 Number Number Number $0.2 million 31 December 2014: $ 0.1 million.
Beginning Balance Arab Bank: is a related party of the Group because one Hikma Pharmaceuticals PLC senior management member is also a board member Granted during the year 118,000 338,808 456,808 of Arab Bank PLC.
Total cash balance at Arab Bank was $55.7 million 31 December 2014: $90.4 million.
Utilisation of facilities granted by Outstanding at 31 December 118,000 338,808 456,808 Arab Bank to the Group amounted to $56.6 million 31 December 2014: $115.0 million.
Interest expense income is within market rate.
The cost of the EIP of $4 million 2014: $nil has been recorded in the consolidated income statement as part of general and American University of Beirut: is a related party of the Group because one board member of the Group is also a trustee of the University.
During 2015, fees of $0.2 million 2014: $0.1 million were paid.
At 31 December 2015, the amount owed to American University of Beirut from the Group amounted to $nil 31 December 2014: $0.1 million.
Operating lease arrangements HikmaCure: The Group holds a 50:50 joint venture JV agreement with MIDROC Pharmaceuticals Limited.
The JV is called HikmaCure.
2015 2014 Hikma and MIDROC invested in HikmaCure in equal proportions and have committed to provide up to $22 million each in cash of which $m $m $2.5 million has been paid in previous periods.
Minimum lease payments under operating leases recognised in profit or loss for the year 8 5 Unimark: During 2015, the Group has impaired the remaining investment balance related to Unimark Remedies Limited.
The exceptional At the balance sheet date, the Group had outstanding commitments for future minimum lease payments under non-cancellable operating impairment of investment was $7 million.
As at 31 December 2015, the Group held a non-controlling interest of 23.1% in Unimark leases, which fall due as follows: Remedies Limited.
During 2015, the Group paid an amount of $nil in relation to a products development agreement 2014: $2.5 million.
Hikmas share in Unimark Remedies Limited is being divested during 2016 for minimal value.
2015 2014 $m $m Haosun: The Group held a non-controlling interest of 30.1% in Hubei Haosun Pharmaceutical Co. Ltd Haosun at 31 December 2015 Within one year 4 2 31 December 2014: 30.1%.
During 2015, total purchases from Haosun were $ 0.6 million 2014: $1.0 million.
In the two to five years inclusive 9 2 After five years 4 Remuneration of key management personnel 17 4 The remuneration of the key management personnel comprising the Executive and Non-Executive Directors and certain of senior management as set out in the Directors Report of the Group is set out below in aggregate for each of the categories specified in IAS 24 Operating lease payments represent rentals payable by the Group for certain of its office properties.
Leases are negotiated for a term of one Related Party Disclosures.
Further information about the remuneration of the individual Directors is provided in the audited part of the to five years.
Remuneration Committee Report on pages 102 to 124.
